Is BICYCLE THERAPEUTICS PLC financially healthy?

BICYCLE THERAPEUTICS PLC scores 1 out of 7 on the Piotroski F-score. Only 7 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.

Who are the largest institutional holders of BICYCLE THERAPEUTICS PLC?

Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are RENAISSANCE TECHNOLOGIES LLC (adding), PRICE T ROWE ASSOCIATES INC /MD/ (trimming), MORGAN STANLEY (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

BICYCLE THERAPEUTICS PLC (BCYC)

Nasdaq · ADR · Pharmaceutical Preparations

One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

1 / 7

FAILReturn on assets positiveROA -30.5%
FAILOperating cash flow positiveOCF -250M
FAILReturn on assets improving-17.7% → -30.5%
FAILCash flow exceeds earningsOCF -250M vs NI -219M
FAILLong-term debt ratio fallingno debt reported
FAILCurrent ratio improving13.81 → 11.98
FAILNo share dilution58M → 69M shares
FAILGross margin improvingno gross profit reported
PASSAsset turnover improving0.04× → 0.10×

Altman Z-score

-0.23distress

Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.

Cash conversion: 114.0%
Share count change: 19.0%

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2020	$10.4M	−$51.0M	−$19.0M	—	19,145,938
FY2021	$11.7M	−$66.8M	−$16.8M	—	25,061,734
FY2022	$14.5M	−$112.7M	−$105.1M	—	29,660,659
FY2023	$27.0M	−$180.7M	−$63.6M	—	35,592,362
FY2024	$35.3M	−$169.0M	−$166.0M	—	58,207,593
FY2025

Ownership flow

9 institutions tracked — 7 added, 2 reduced. Active managers added 716,686 shares while index money cut 4,383.

Institutional holders of BICYCLE THERAPEUTICS PLC and their share-count change
Manager	Kind	Shares	Change	Value
RENAISSANCE TECHNOLOGIES LLC	Hedge fund	1,533,400	+554,100	$6.5M
CITADEL ADVISORS LLC	Hedge fund	627,725	+217,040	$2.7M
PRICE T ROWE ASSOCIATES INC /MD/	Active fund	902,150	−126,093	$3.8M
MORGAN STANLEY	Active fund	667,269

Capital returned

What the company actually paid out and bought back, as reported — the record behind any yield figure.

Dividend per share

2026Q1: $0.00
2025Q1: $0.00
2024Q1: $0.00
2023Q1: $0.00
2022Q1: $0.00
2021Q1: $0.00

Identity

CIK: 0001761612
LEI: 213800XKUI6R7GKC3E43
FIGI: BBG00P0YWPK6
SIC: 2834 · Pharmaceutical Preparations
Incorporated: United Kingdom
Headquarters: CAMBRIDGE, United Kingdom

Ownership

Institutional: 72.0%
Institutions: 127
Insiders: 4.4%

Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.

Questions about BICYCLE THERAPEUTICS PLC

Is BICYCLE THERAPEUTICS PLC financially healthy?: BICYCLE THERAPEUTICS PLC scores 1 out of 7 on the Piotroski F-score. Only 7 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of BICYCLE THERAPEUTICS PLC?: Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are RENAISSANCE TECHNOLOGIES LLC (adding), PRICE T ROWE ASSOCIATES INC /MD/ (trimming), MORGAN STANLEY (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

This page is one panel of the terminal

The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.

Download the terminal See pricing

Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.